More than 40% of these treatments were for rare or difficult-to-treat conditions, including hepatitis C, meningococcal B, and metastatic melanoma.
Plus de 40 % de ces médicaments concernent des maladies rares ou difficiles à traiter, telles que l’hépatite C, le méningocoque B, ou encore le mélanome métastatique.